new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)





Similar
Filing Names

Curevac Gmbh
Curevac Gmbh xdb
  

Curevac Gmbh patents

Recent patent applications related to Curevac Gmbh. Curevac Gmbh is listed as an Agent/Assignee. Note: Curevac Gmbh may have other listings under different names/spellings. We're not affiliated with Curevac Gmbh, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Curevac Gmbh-related inventors




Date Curevac Gmbh patents (updated weekly) - BOOKMARK this page
03/24/16Application of mrna for use as a therapeutic against tumour diseases
11/12/15Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
10/29/15Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
09/17/15Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
08/06/15Artificial nucleic acid molecules for improved protein or peptide expression
07/02/15Artificial nucleic acid molecules
06/18/15Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
05/21/15Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
04/30/15Negatively charged nucleic acid comprising complexes for immunostimulation
04/30/15Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
04/16/15Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
04/02/15Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
02/26/15Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
02/19/15Artificial nucleic acid molecules comprising a 5'top utr
02/05/15Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
01/29/15Application of mrna for use as a therapeutic against tumour diseases
10/02/14Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
02/06/14Complexes of rna and cationic peptides for transfection and for immunostimulation
12/19/13Vaccination in newborns and infants
11/07/13Vaccination in elderly patients
10/24/13Combination of vaccination and inhibition of mhc class i restricted antigen presentation
10/03/13Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
09/26/13Composition for treating prostate cancer (pca)
08/08/13Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
08/01/13Rna-coded antibody
06/06/13Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
05/16/13Nucleic acid of formula (i): glxmgn, or (ii): clxmcn, in particular as an immune-stimulating agent/adjuvant
08/30/12Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
08/23/12Combination therapy for immunostimulation
01/12/12Transfection of blood cells with mrna for immune stimulation and gene therapy
12/22/11Application of mrna for use as a therapeutic against tumour diseases
11/03/11Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
10/13/11Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
03/31/11Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
03/03/11Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
12/02/10Immunostimulation by chemically modified rna
09/23/10Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
08/12/10Complexes of rna and cationic peptides for transfection and for immunostimulation
02/25/10Base-modified rna for increasing the expression of a protein
12/31/09Nucleic acid of formula (i): gixmgn, or (ii): cixmcn, in particular as an immune-stimulating agent/adjuvant
01/26/12Nucleic acids comprising formula (nuglxmgnnv)a and derivatives thereof as immunostimulating agent/adjuvant







ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Curevac Gmbh in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Curevac Gmbh with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';